AHP/INTERNEURON REDUX PATIENT PACKAGE INSERT TO BE DEVELOPED; ANTI-OBESITY AGENT WILL COST $2.40/DAY AT JUNE LAUNCH; DEXFENFLURAMINE IS DEA SCHEDULE IV
A patient package insert for Interneuron/Wyeth-Ayerst's anti-obesity drug Redux will be submitted to FDA as an NDA supplement, according to the agency's April 29 approval letter for the anti-obesity agent dexfenfluramine.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth